16 results on '"Ceribelli, Angela"'
Search Results
2. List of Contributors
- Author
-
Allsopp, Philip, primary, Bonaccio, Marialaura, additional, Brown, Duncan T., additional, Brown, Emma M., additional, Bruni, Renato, additional, Calani, Luca, additional, Cavalieri, Duccio, additional, Ceppa, Florencia, additional, Ceribelli, Angela, additional, Cirlini, Martina, additional, Costabile, Adele, additional, Cuva, Simone, additional, Dall’Asta, Chiara, additional, De Filippo, Carlotta, additional, Del Rio, Daniele, additional, Donati, Maria Benedetta, additional, Fava, Francesca, additional, Furlanello, Cesare, additional, de Gaetano, Giovanni, additional, Gasperotti, Mattia, additional, Gill, Chris I.R., additional, Hullar, Meredith A.J., additional, Iacoviello, Licia, additional, Klinder, Annett, additional, Koutsos, Athanasios, additional, Lampe, Johanna W., additional, Lancaster, Samuel M., additional, Lovegrove, Julie A., additional, Maitin, Vatsala, additional, Mancini, Andrea, additional, McMullan, Geoff, additional, Mena, Pedro, additional, Morelli, Lorenzo, additional, Patrone, Vania, additional, Pounis, George, additional, Rowland, Ian, additional, Scott, Karen P., additional, Selmi, Carlo, additional, Shen, Qing, additional, van Sinderen, Douwe, additional, Ternan, Nigel G., additional, Tuohy, Kieran M., additional, Turroni, Francesca, additional, Ventura, Marco, additional, Venuti, Paola, additional, Vrhovsek, Urska, additional, and Yoder, Seth C., additional
- Published
- 2015
- Full Text
- View/download PDF
3. Antimitochondrial Antibodies
- Author
-
Selmi, Carlo, primary, Ceribelli, Angela, additional, and Gershwin, M. Eric, additional
- Published
- 2014
- Full Text
- View/download PDF
4. Autoantibodies to Survival of Motor Neuron (SMN) Complex
- Author
-
Satoh, Minoru, primary, Chan, Jason Y.F., additional, Ceribelli, Angela, additional, and Chan, Edward K.L., additional
- Published
- 2014
- Full Text
- View/download PDF
5. Antinuclear Antibodies
- Author
-
Ceribelli, Angela, primary, Satoh, Minoru, additional, and Chan, Edward K.L., additional
- Published
- 2014
- Full Text
- View/download PDF
6. List of Contributors
- Author
-
Abu-Shakra, Mahmoud, primary, Alard, Jean-Eric, additional, Amital, Howard, additional, Andreoli, L., additional, Antico, Antonio, additional, Antonelli, Alessandro, additional, Aoki, Christopher A., additional, Arepally, Gowthami, additional, Asashima, Hiromitsu, additional, Atzeni, Fabiola, additional, Bagnasco, Marcello, additional, Barcellini, Wilma, additional, Bayry, Jagadeesh, additional, Bendtzen, Klaus, additional, Ben-Nun, Avraham, additional, Berden, Jo H.M., additional, Bernareggi, Davide, additional, Bertolaccini, Maria Laura, additional, Bizzaro, Nicola, additional, Bogdanos, Dimitrios, additional, Borghi, Maria O., additional, Bowlus, Christopher L., additional, Božič, Borut, additional, Calise, S. John, additional, Caneparo, Valeria, additional, Canevari, Silvana, additional, Carcamo, Wendy C., additional, Carp, Howard J.A., additional, Cavazzana, Ilaria, additional, Ceribelli, Angela, additional, Cervera, Ricard, additional, Chan, Edward K.L., additional, Chan, Happy, additional, Chan, Jason Y.F., additional, Chang, Christopher, additional, Chapple, Katie, additional, Chiang, Bor-Luen, additional, Chighizola, Cecilia B., additional, Christen, Urs, additional, Ciavarella, Teresa, additional, Cicardi, Marco, additional, Cines, Douglas B., additional, Eschler, Deirdre Cocks, additional, Conrad, Karsten, additional, Coutinho, Ester, additional, Crotti, Chiara, additional, Csernok, Elena, additional, Čuc čnik, Sasa, additional, Cugno, Massimo, additional, Cuker, Adam, additional, Czarnocka, Barbara, additional, de Andrea, Marco, additional, Dell’Oste, Valentina, additional, De Los Reyes Labitigan, Monalyn, additional, Dominguez, Yasmany, additional, Einav, Yulia, additional, Fallahi, Poupack, additional, Feist, Eugen, additional, Ferri, Clodoveo, additional, Figini, Mariangela, additional, Fisher, Benjamin A., additional, Franceschini, Franco, additional, Fredi, M., additional, Fritzler, Marvin J., additional, Gariglio, Marisa, additional, Gerosa, Maria, additional, Gershwin, M. Eric, additional, Giometto, Bruno, additional, Giuggioli, Dilia, additional, Godlewska, Marlena, additional, Gross, Wolfgang L., additional, Grossman, Chagai, additional, Gualtierotti, Roberta, additional, Hamann, Dörte, additional, Harel, Michal, additional, Hershko, Alon Y., additional, Hiepe, Falk, additional, Hodak, Emmilia, additional, Huda, Saif, additional, Hultman, Per, additional, Iizuka, Mana, additional, Invernizzi, Pietro, additional, Jamin, Christophe, additional, Juan, Manel, additional, Kallenberg, Cees G.M., additional, Kapsogeorgou, Efstathia K., additional, Karussis, Dimitrios, additional, Kaushansky, Nathali, additional, Kaveri, Srini V., additional, Kawakita, Satoru, additional, Kazatchkine, Michel D., additional, Khamashta, Munther A., additional, Khan, Farah, additional, Küpper, Jan-Heiner, additional, Kveder, Tanja, additional, Lacroix-Desmazes, Sébastien, additional, Lakota, Katja, additional, Landolfo, Santo, additional, Lang, Bethan, additional, Lazúrová, Ivica, additional, Le Meur, Yannick, additional, Lerner, Aaron, additional, Li, Yi, additional, Liberal, Rodrigo, additional, Lidar, Merav, additional, Linington, Christopher, additional, Lima, Breno R., additional, Lleo, Ana, additional, Lopez, Luis R., additional, Maddison, Paul, additional, Mahler, Michael, additional, Matsumoto, Isao, additional, Matsuura, Eiji, additional, Meroni, Pier Luigi, additional, Mieli-Vergani, Giorgina, additional, Mimouni, Daniel, additional, Mrak-Poljsak, Katjusa, additional, Muller, Sylviane, additional, Muratori, Luigi, additional, Naguwa, Stanley M., additional, Naparstek, Yaakov, additional, Nobile-Orazio, Eduardo, additional, Nussenblatt, Robert B., additional, Pasvolsky, Oren, additional, Patil, Veerupaxagouda, additional, Paz, Damien Luque, additional, Paz, Ziv, additional, Pelizza, Federica, additional, Penatti, Alessandra, additional, Pengo, Vittorio, additional, Perricone, Carlo, additional, Perricone, Roberto, additional, Pers, Jacques-Olivier, additional, Petríková, Jana, additional, Petrou, Panayiota, additional, Piantoni, S., additional, Pietropaolo, Massimo, additional, Pittock, Sean J., additional, Pollard, K. Michael, additional, Pregnolato, Francesca, additional, Pura, Mikuláš, additional, Putterman, Chaim, additional, Radice, Antonella, additional, Raschi, Elena, additional, Ravindranath, Mepur H., additional, Reeves, Westley H., additional, Renaudineau, Yves, additional, Rinaldi, Maurizio, additional, Roggenbuck, Dirk, additional, Ronda, Nicoletta, additional, Rose, Noel R., additional, Rosenberg, Nurit, additional, Rozman, Blaž, additional, Ruffatti, Amelia, additional, Sarzi-Puttini, Piercarlo, additional, Satoh, Minoru, additional, Sciascia, Savino, additional, Scofield, R. Hal, additional, Sebastiani, Marco, additional, Selmi, Carlo, additional, Nida Sen, H., additional, Shenkman, Boris, additional, Shoenfeld, Yehuda, additional, Sinico, Renato Alberto, additional, Smeenk, Ruud J.T., additional, Sodin-Semrl, Snezna, additional, Sperling, Mark A., additional, Steenholdt, Casper, additional, Stöcker, Winfried, additional, Strassburg, Christian P., additional, Suffritti, Chiara, additional, Sumida, Takayuki, additional, Tampoia, Marilina, additional, Tedeschi, Alberto, additional, Tedesco, Francesco, additional, Terasaki, Paul I., additional, Tincani, Angela, additional, Tomer, Yaron, additional, Tonutti, Elio, additional, Toothaker, Thomas B., additional, Tozzoli, Renato, additional, Tsokos, George C., additional, Tsuboi, Hiroto, additional, Tzioufas, Athanasios G., additional, Ulmansky, Rina, additional, Usuki, Seigo, additional, Vaknin-Dembinsky, Adi, additional, van der Vlag, Johan, additional, Vergani, Diego, additional, Villalta, Danilo, additional, Vincent, Angela, additional, Weiner, Maya Ram, additional, Wener, Mark H., additional, Wiik, Allan, additional, Witte, Torsten, additional, Yang, Li-Jun, additional, Yang, Yao-Hsu, additional, Youinou, Pierre, additional, Yu, Hsin-Hui, additional, Yu, Robert K., additional, Zandman-Goddard, Gisele, additional, Zanella, Alberto, additional, Zanichelli, Andrea, additional, Zavdy, Ofir, additional, Zhuang, Haoyang, additional, and Zigon, Polona, additional
- Published
- 2014
- Full Text
- View/download PDF
7. Antibodies to Rods and Rings
- Author
-
Calise, S. John, primary, Carcamo, Wendy C., additional, Ceribelli, Angela, additional, Dominguez, Yasmany, additional, Satoh, Minoru, additional, and Chan, Edward K.L., additional
- Published
- 2014
- Full Text
- View/download PDF
8. Anti-phospholipid antibody prevalence and association with subclinical atherosclerosis and atherothrombosis in the general population.
- Author
-
Selmi C, De Santis M, Battezzati PM, Generali E, Lari SA, Ceribelli A, Isailovic N, Zermiani P, Neidhöfer S, Matthias T, Scirè CA, Baldassarre D, and Zuin M
- Subjects
- Adolescent, Adult, Aged, Atherosclerosis epidemiology, Biomarkers blood, Cross-Sectional Studies, Female, Heart Diseases epidemiology, Humans, Italy epidemiology, Male, Middle Aged, Prevalence, Random Allocation, Thrombosis epidemiology, Young Adult, Antibodies, Antiphospholipid blood, Atherosclerosis blood, Heart Diseases blood, Population Surveillance, Thrombosis blood
- Abstract
Background: There is no agreement on the prevalence of anti-phospholipid antibodies (aPLs) and the correlation with atherosclerosis and cardiovascular (CV) events in the general population., Methods: We performed a cross-sectional study on 1712 randomly enrolled subjects from a Northern Italian city to investigate the presence of aPLs and the association with subclinical atherosclerosis (using the carotid artery intima media thickness measured as inter-adventitia common carotid artery diameters - ICCAD) and retrospectively collected CV factors and events (i.e. acute myocardial infarction, stroke, and peripheral obliterans arterial vasculopathy) using physician-assisted questionnaires. We tested serum IgG, IgM, and IgA anti-cardiolipin, anti-beta2glycoprotein I (aGPI), and anti-phosphatidylserine-prothrombin antibodies., Results: Positive aPLs were found in 15.1% of the subjects, with no differences between sex but with higher rates in older subjects. Carotid subclinical atherosclerosis was more frequent in aPL positive subjects; more specifically, aGPI IgA were associated with higher ICCAD average (adjusted beta 0.51, 95% confidence interval (CI)0.17-0.84; p = 0.003). A positive history of CV events was also more frequent in aPL positive subjects (odds ratio (OR) 1.67, 95%CI 1.08-2.54; p = 0.012), particularly peripheral obliterans arterial vasculopathy (OR 2.02; 95%CI 1.14-3.57; p = 0.015). Among subjects with a Framingham risk score >20, and/or diabetes, and/or body mass index >35 kg/m
2 , aPL positivity was associated to the highest risk of CV events (OR 2.52, 95%CI 1.24-5.11; p = 0.011)., Conclusions: APL prevalence in the general population is higher than previously reported. CV events and subclinical atherosclerosis are more frequent in the presence of aPL, particularly when a high CV risk coexists., (Copyright © 2019 Elsevier B.V. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
9. Systemic rheumatic diseases: From biological agents to small molecules.
- Author
-
Sarzi-Puttini P, Ceribelli A, Marotto D, Batticciotto A, and Atzeni F
- Subjects
- Biosimilar Pharmaceuticals therapeutic use, Humans, Antirheumatic Agents therapeutic use, Rheumatic Diseases drug therapy
- Abstract
The development of biologics and small oral molecules has recently changed the scenario of pharmacologic treatment of systemic rheumatic diseases and it has become a real revolution. These drugs have innovative mechanisms of action, based on the inhibition of specific molecular or cellular targets directly involved in disease pathogenesis. This new scenario has lead to a regular update of the management recommendations of several institutions, such as those for Rheumatoid Arthritis treatment that address the use of conventional and biologic therapies including TNF inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, IL-6 inhibitors (tocilizumab and sarilumab), biosimilars and small oral molecules (the JAK inhibitors tofacitinib and baricitinib). Monotherapy, combination therapy, treatment strategies (such as treat-to-target) and the targets of sustained clinical remission or low disease activity are the final goal of the guidelines for rheumatic patients management. In another condition represented by Axial Spondyloarthritis guidelines suggest to start first with non-steroidal anti-inflammatory drugs to improve lifestyle and reduce spine inflammation, but if this is not achieved in 2-4 weeks it is important to consider the use of local therapies (i.e. glucocorticoid injections) or to start biologic therapy such as TNF inhibitors and then eventually switching to another TNF inhibitor or swapping to IL-17 inhibitor. In the case of active Psoriatic Arthritis, guidelines suggest to start with non-steroidal anti-inflammatory drugs and even local glucocorticoid injections especially for oligoarthritis, then to start conventional therapies if lack of efficacy, and finally start biologics or small oral molecules in the presence of drugs toxicity, unfavorable prognostic factors and still active arthritis. In several cases, active Psoriatic Arthritis patients develop a complex clinical condition with comorbidities such as diabetes, inflammatory bowel disease and high risk of infections, and for this reason the American College of Rheumatology and the National Psoriasis Foundation have developed specific guidelines for their management. Biologic and new small molecules therapies are very expensive, but the availability of biosimilars offers the opportunity of reducing the treatment cost and significantly decreasing the cost of originators as well. In fact, we live in a period characterized by the need to rationalize costs of these drugs, to allow treating a higher number of patients and to maintain a homogeneous possibility of treatment choice. For these reasons, we need to follow scientific guidelines and patients' clinical conditions to choose the correct treatment, also based on the economic burden of therapies., (Copyright © 2019 Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
10. Detection of anti-mitochondrial antibodies by immunoprecipitation in patients with systemic sclerosis.
- Author
-
Ceribelli A, Isailovic N, De Santis M, Generali E, Satoh M, and Selmi C
- Subjects
- Aged, Aged, 80 and over, Autoantibodies blood, Bile Ducts pathology, Cholangitis diagnosis, Female, Humans, Immunoprecipitation methods, Italy, Male, Middle Aged, Mitochondria immunology, Protein Serine-Threonine Kinases immunology, Pyruvate Dehydrogenase Acetyl-Transferring Kinase, Scleroderma, Systemic diagnosis, Cholangitis immunology, Immunodominant Epitopes metabolism, Mitochondria metabolism, Protein Serine-Threonine Kinases metabolism, Scleroderma, Systemic immunology
- Abstract
Objective: To describe a new immunoprecipitation pattern identified in Italian patients affected by systemic sclerosis (SSc), corresponding to the pyruvate dehydrogenase antigen complex recognized by anti-mitochondrial antibodies (AMA) in primary biliary cholangitis (PBC)., Methods: Autoantibodies in sera from 85 patients with SSc were tested by protein- and RNA-immunoprecipitation. Immunoprecipitation-Western blot was used to determine the identified proteins, and medical records re-evaluated for liver function tests and PBC., Results: In 13/85 (15%) SSc sera, a unique set of 75-50-40-34kD proteins that had not been previously reported, was noted. The four proteins were identified as the proteins X/E3BP, E1α, E1β, and E2/E3 of the pyruvate dehydrogenase antigen complex by immunoprecipitation-Western blot. From clinical record evaluation, 9/13 (69%) SSc patients with this new pattern were positive for AMA by routine indirect immunofluorescence, and 7/13 (54%) had a diagnosis of PBC, while 4/13 (31%) manifested no biochemical signs of cholestasis. Twelve of 13 patients with SSc and AMA by immunoprecipitation have a limited cutaneous form of SSc and anti-centromere antibodies., Conclusions: We describe a pattern of 4 proteins in 15% of SSc patients, identified for the first time by protein-immunoprecipitation. This pattern corresponds to serum AMA against the pyruvate dehydrogenase antigen complex and it must be considered in the interpretation of protein-immunoprecipitation results., (Copyright © 2017 Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
11. Testing for myositis specific autoantibodies: Comparison between line blot and immunoprecipitation assays in 57 myositis sera.
- Author
-
Cavazzana I, Fredi M, Ceribelli A, Mordenti C, Ferrari F, Carabellese N, Tincani A, Satoh M, and Franceschini F
- Subjects
- Adenosine Triphosphatases immunology, Adult, DNA-Binding Proteins immunology, Female, Humans, Immunoprecipitation, Interferon-Induced Helicase, IFIH1 immunology, K562 Cells, Male, Middle Aged, Myositis diagnosis, Retrospective Studies, Sensitivity and Specificity, Transcription Factors immunology, Antibodies, Antinuclear blood, Immunoassay methods, Myositis blood
- Abstract
Objective: To analyze the performance of a line blot assay for the identification of autoantibodies in sera of patients affected by myositis, compared with immunoprecipitation (IP) as gold standard., Methods: 66 sera of patients with myositis (23 polymyositis, 8 anti-synthetase syndromes, 29 dermatomyositis and 6 overlap syndromes) were tested by commercial LB (Euroimmun, Lubeck, Germany); 57 sera were analyzed also by IP of K562 cell extract radiolabeled with (35)S-methionine. Inter-rater agreement was calculated with Cohen's k coefficient., Results: Myositis-specific antibodies (MSA) were detected in 36/57 sera (63%) by IP and in 39/66 sera (59%) by LB. The most frequent MSA found by LB were anti-Jo1 and anti-Mi2 found in 15% (10/66) of sera, followed by anti-NXP2 and anti-SRP detected in 106% (7/66) of sera. Anti-TIF1gamma and anti-MDA5 were found in 6 (9%) and 5 sera (7.6%), respectively. A good agreement between methods was found only for anti-TIF1γ, anti-MDA5 and anti-NXP-2 antibodies, while a moderate agreement was estimated for anti-Mi2 and anti-EJ. By contrast, a high discordance rate for the detection of anti-Jo1 antibodies was evident (k: 0.3). Multiple positivity for MSA were found in 11/66 (17%) by LB and 0/57 by IP (p: 0001). Comparing the clinical features of these 11 sera, we found total discrepancies between assays in 3 sera (27.3%), a relative discrepancy due to the occurrence of one discordant autoantibody (not confirmed by IP) in 5 cases (45.5%) and a total discrepancy between LB and IP results, but with a relative concordance with clinical features were found in other 3 sera (27.3%). The semiquantitative results do not support the interpretation of the data., Conclusions: The use of LB assay allowed the detection of new MSA, such as anti-MDA5, anti-MJ and anti-TIF1gamma antibodies, previously not found with routine methods. However, the high prevalence of multiple positivities and the high discondant rate of anti-Jo1 antibodies could create some misinterpretation of the results from the clinical point of view. These data should be confirmed by enlarging the number of myositis cases., (Copyright © 2016 Elsevier B.V. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
12. Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15 years.
- Author
-
Selmi C, Ceribelli A, Generali E, Scirè CA, Alborghetti F, Colloredo G, Porrati L, Achenza MI, De Santis M, Cavaciocchi F, Massarotti M, Isailovic N, Paleari V, Invernizzi P, Matthias T, Zucchi A, and Meroni PL
- Subjects
- Age Distribution, Antibodies, Antinuclear immunology, Antigens, Nuclear immunology, Connective Tissue Diseases diagnosis, Connective Tissue Diseases immunology, Humans, Prevalence, Sex Characteristics, Antibodies, Antinuclear blood, Antigens, Nuclear blood, Connective Tissue Diseases epidemiology
- Abstract
The prevalence of ANA and anti-ENA in the general population is not well established, especially their clinical significance in healthy subjects. We herein determined the prevalence and predictive value of serum ANA and anti-ENA for connective tissue diseases (CTD), cancer, and mortality. We took advantage of a randomly selected sample of the 1998 general population (Isola I) consisting of 2828 subjects (53% women, age 43±13 years) from a well-defined Northern Italian area. Serum ANA and anti-ENA were tested on the 2690 samples available in 2012 (Isola II, 50% women, age 58±13 years). Administrative databases were searched for CTD, cancer diagnosis, and death cases occurring between enrollment and December 31, 2013. The hazard ratio (HR) was calculated for incident cases. Serum ANA is positive in 18.1% for any titer and 6.1% for titers ≥1:160, 23% in subjects over 50 years and 13.1% and 6.1% for any titer and titers ≥1:160, respectively, in women. The HR for CTD development was significantly high for all ANA titers, with the highest for ANA ≥1:160 (HR 14.19, 95% CI 3.07-65.68). ANA positivity was not associated with cancer (HR 1.03; 95% CI 0.75-1.43), or with mortality (HR adjusted for age and sex 1.40; 95% CI 0.94-2.09). Serum anti-ENA is positive in a minority of subjects with highest figures for anti-nucleosome (1.9%), -histone (1.6%) and -PM/Scl (1.5%). In conclusion, serum ANA prevalence in the general population is highest in senior subjects and in women, while the female predominance is significantly lower compared to overt CTD. Serum ANA is associated with an increased probability of CTD development over time, but does not influence survival or cancer risk., (Copyright © 2015 Elsevier B.V. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
13. Seronegative reactive spondyloarthritis and the skin.
- Author
-
Generali E, Ceribelli A, Massarotti M, Cantarini L, and Selmi C
- Subjects
- Antibodies blood, Arthritis, Reactive blood, Humans, Spondylarthritis blood, Arthritis, Reactive complications, Skin Diseases etiology, Spondylarthritis complications
- Abstract
Spondyloarthritidies represent a group of conditions affecting the axial and peripheral muscoloskeletal apparatus and are often associated with psoriasis, infections, and inflammatory bowel diseases. Other diseases included in this category are psoriatic arthritis, ankylosing spondylitis, and enteropathic arthritis. Reactive arthritis is an elusive spondyloarthritis, commonly occurring 1 to 3 weeks after a digestive or a genitourinary tract infection, in which microorganisms do not infect the joint directly. Reactive arthritis is classically characterized by large-joint arthritis, urethritis in men and cervicitis in women, and eye inflammation (usually conjunctivitis or uveitis) but encompasses numerous other symptoms and signs, including manifestations of dermatologic interest such as keratoderma blenorrhagicum and circinate balanitis. The diagnosis of reactive arthritis is clinical, and the infectious agent cannot always be identified due to disease latency after the infection. Most cases are self-limiting, but reactive arthritis may become chronic in 30% of cases. Treatment options include anti-inflammatory drugs, steroids, and sulfasalazine; biologic agents, such as tumor necrosis factor α (TNF-α) blockers, have been recently used, but there are only a few randomized clinical trials on the treatment of reactive arthritis. The effectiveness of antimicrobials needs further evaluation., (Copyright © 2015 Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
14. MicroRNAs and autoimmunity.
- Author
-
Ceribelli A, Satoh M, and Chan EK
- Subjects
- Adaptive Immunity physiology, Autoimmune Diseases immunology, Humans, Immunity, Innate physiology, Autoimmunity immunology, MicroRNAs physiology
- Abstract
The role of microRNAs (miRNAs) in the regulation of many physiological and pathological processes has been intensely studied in recent years. Some miRNAs, such as miR-146a and miR-182, play a dominant role in the regulation of the innate and adaptive immune responses, respectively. Many miRNAs are reportedly deregulated in autoimmune diseases, but miR-146a in particular seems to be consistently altered. The overexpression or underexpression of miRNAs can influence specific targets and pathways, leading to autoimmune disease phenotypes, and this is supported also by some in vivo studies. Targeting miRNAs could represent a valid future therapeutic option for autoimmune diseases., (Copyright © 2012 Elsevier Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
15. Elastic properties of the ascending aorta in patients with rheumatoid arthritis.
- Author
-
Vizzardi E, Cavazzana I, Pezzali N, Ceribelli A, Bazzani C, Tincani A, Metra M, Franceschini F, and Cas LD
- Subjects
- Adult, Aged, Aorta physiology, Arthritis, Rheumatoid complications, Arthritis, Rheumatoid physiopathology, Humans, Male, Middle Aged, Vasoconstriction physiology, Vasodilation physiology, Aorta pathology, Arthritis, Rheumatoid pathology, Elasticity physiology
- Published
- 2011
- Full Text
- View/download PDF
16. Anti-RNA polymerase III antibodies: a marker of systemic sclerosis with rapid onset and skin thickening progression.
- Author
-
Cavazzana I, Ceribelli A, Airo' P, Zingarelli S, Tincani A, and Franceschini F
- Subjects
- Antibody Specificity, Autoantibodies immunology, Biomarkers blood, Disease Progression, Female, Humans, Male, Middle Aged, Scleroderma, Systemic blood, Skin immunology, Autoantibodies blood, RNA Polymerase III immunology, Scleroderma, Systemic immunology, Scleroderma, Systemic pathology, Skin pathology
- Abstract
Anti-RNA polymerase III antibodies (ARA) are a specific marker for Systemic Sclerosis (SSc), associated to severe disease with major organ and diffuse cutaneous involvement. In our series, ARA were found in 19 of 216 sera, in 15 cases as isolated antibodies' specificity, with a statistically negative association with other SSc-specific autoantibodies (p: 0.00003). The prevalence of ARA among 73 anticentromere and anti-topoisomerase I (topo I) negative sera, was 20.5%. Patients with isolated ARA had more rapid disease onset, defined as the interval from the appearance of Raynaud's phenomenon to the first symptom other than Raynaud's, than patients with isolated anti-topo I antibodies (median: 2 months vs 13 months; p: 0.0013). A rapid onset of SSc (within 6 months from Raynaud's phenomenon onset) was found in all patients with isolated ARA and only in 34% of those with anti-topo I (p<0.00001). Moreover, the skin thickening in the first months after SSc onset was faster in the ARA group (p<0.0001). Nevertheless, the rates of internal organ involvement and of survival rates were similar between the two groups. Our experience therefore suggests that ARA are a marker of very rapid onset of disease and skin thickening progression in SSc.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.